Crossmark

Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-019-5722-1

Published Online: 2019-05-31

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schiffmann, Lars M. https://orcid.org/0000-0002-2320-5004
Göbel, Heike

Löser, Heike

Schorn, Fabian

Werthenbach, Jan Paul

Fuchs, Hans F.

Plum, Patrick S.

Bludau, Marc

Zander, Thomas

Schröder, Wolfgang

Bruns, Christiane J.

Kashkar, Hamid

Quaas, Alexander

Gebauer, Florian
Funding

Funding for this research was provided by:

Köln Fortune Program, University of Cologne, Faculty of Medicine (408/2018)

Deutsche Krebshilfe (70112113)

Deutsche Forschungsgemeinschaft (CRU 286, CRC1218)

Deutsche Forschungsgemeinschaft (KA 2853/4-1)
License Information

Text and Data Mining valid from 2019-05-31

Version of Record valid from 2019-05-31
More Information

Article History

Received: 19 February 2019

Accepted: 16 May 2019

First Online: 31 May 2019

Ethics approval and consent to participate

: The study was performed in agreement with the local research ethics guidelines (ethics committee medical faculty, University of Cologne). Human samples were collected at the University Hospital of Cologne with written informed consent concurring with the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below